The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Avelumab in platinum-resistant/refractory ovarian cancer did not meet OS and PFS endpoints

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced the phase III JAVELIN Ovarian 200 trial evaluating avelumab alone or in combination with pegylated liposomal doxorubicin, a type of chemotherapy, compared with PLD did not meet the prespecified primary endpoints of overall survival or progression-free survival in patients with platinum-resistant or -refractory ovarian cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

Addressing high cancer mortality in Native Hawaiian and Pacific Islander populations
A call for equity in cancer research

After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities. 
By Naoto T. Ueno
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account